Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

@article{Moynihan2016EradicationOL,
  title={Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses},
  author={Kelly D Moynihan and Cary Francis Opel and Gregory L Szeto and Alice Tzeng and Eric F. Zhu and Jesse M. Engreitz and Robert T Williams and Kavya Rakhra and Michael H Zhang and Adrienne M Rothschilds and Sudha Kumari and Ryan L Kelly and Byron H Kwan and Wuhbet D. Abraham and Kevin Zeng Hu and Naveen K. Mehta and Monique J. Kauke and Heikyung Suh and Jennifer R. Cochran and Douglas A. Lauffenburger and K Dane Wittrup and Darrell J Irvine},
  journal={Nature Medicine},
  year={2016},
  volume={22},
  pages={1402-1410}
}
Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte–associated protein (CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor regression in metastatic cancer, but these dramatic responses are confined to a minority of patients. This suboptimal outcome is probably due in part to the complex network of immunosuppressive pathways present in advanced tumors, which are unlikely to be overcome by intervention at a single signaling checkpoint. Here we… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 63 references

Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

  • Nelson, M.H
  • J. Immunother. Cancer 4,
  • 2016

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

  • Carreno, B.M
  • Science 348,
  • 2015

Similar Papers

Loading similar papers…